
The Project HERCULES Steering Group is the decision-making body which oversees the delivery of the objectives of Project HERCULES. The group meets twice a year and is chaired by Fleur Chandler.
Access to Project HERCULES Steering Group content is restricted to Steering Group members only.
Project HERCULES team
Members include:
- Fleur Chandler (Chair), Duchenne UK and Sanofi UK
- Emily Reuben, Duchenne UK
- Josie Godfrey, JG Zebra Consulting
Companies
Members include representatives from:
- Astellas Pharma Inc
- Catabasis Pharmaceuticals Inc
- Pfizer Inc
- PTC Therapeutics International Limited,
- Roche
- Sarepta Therapeutics Inc
- Solid Biosciences LLC
- Santhera Pharmaceuticals Holding AG
- Wave Life Sciences USA
Patient groups
Members include representatives from:
- PPMD (US)
- World Duchenne Organisation (UPPMD)
- Save Our Sons (Australia)
- Stand For Duchenne Canada
- Jesse’s Journey (Canada)
Advisers
- Prof Ron Akehurst, BresMed
- Meriem Bouslouk, Independent German HTA expert
- Merce Obach Cortadellas, Catsalut
- Prof Jalpa Doshi, University of Pennsylvania
- Karen Facey, University of Edinburgh
- Dr Michela Guglieri, Newcastle University
- Anthony Hatswell, Delta Hat
- Jane Larkindale, C-Path (US)
- Dr Anna Sarkozy, GOSH London
- Juliana Setyawan, US
- James Signorovitch and Susan Ward, cTAP (US)
- Ian Watson, NICE
- Dr Jarod Wong, University of Glasgow
Vendors
Vendors also attend the Steering Group:
- Aparito
- HCD Economics
- Oxford University Innovation
- Pharmatelligence
- Sheffield School of Health and Related Research (ScHARR)
- Source HEOR
- Tolley Health Economics
- University of Leicester